Because an oral 15-PGDH inhibitor has already passed Phase 1 safety testing in humans for age-related #muscle weakness, the authors are hopeful that clinical trials in joint disease will follow, potentially paving the way for #nonsurgical, cartilage-regenerating therapies that could delay or replace knee and hip replacements
If youre conducting studies, ensure proper dosing, storage, and monitoring to minimize risks
Dominant negative Gs (DNGs) includes mutations S54N, G226A, E268A, N271K, K274D, R280K, T284D, I285T and A366S of Gs, which has been described preciously to reduce nucleotide binding affinities and enhance the stability of GLP-1R and Gs heterotrimer complex(Liang, Belousoff, Fletcher, et al
Going beyond this introduces increasing uncertainty about both potency and sterility